IciStem 队列中异体造血干细胞移植后艾滋病毒持续存在的病毒学和免疫学标志物的动态变化:一项前瞻性观察队列研究。

IF 12.8 1区 医学 Q1 IMMUNOLOGY
Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera, Björn-Erik Ole Jensen, Linos Vandekerckhove, Manuel Jurado, Kavita Raj, Julian Schulze Zur Wiesch, Rebeca Bailén, Johanna M Eberhard, Mitja Nabergoj, Gero Hütter, Raquel Saldaña-Moreno, Sharon Oldford, Lisa Barrett, Maria Luisa Montes Ramirez, Salisu Garba, Ravi Kumar Gupta, Boris Revollo, Christelle Ferra-Coll, Jurgen Kuball, Galit Alter, Asier Sáez-Cirión, Jose Luis Diez-Martin, Elizabeth R Duke, Joshua T Schiffer, Annemarie Wensing, Javier Martinez-Picado
{"title":"IciStem 队列中异体造血干细胞移植后艾滋病毒持续存在的病毒学和免疫学标志物的动态变化:一项前瞻性观察队列研究。","authors":"Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera, Björn-Erik Ole Jensen, Linos Vandekerckhove, Manuel Jurado, Kavita Raj, Julian Schulze Zur Wiesch, Rebeca Bailén, Johanna M Eberhard, Mitja Nabergoj, Gero Hütter, Raquel Saldaña-Moreno, Sharon Oldford, Lisa Barrett, Maria Luisa Montes Ramirez, Salisu Garba, Ravi Kumar Gupta, Boris Revollo, Christelle Ferra-Coll, Jurgen Kuball, Galit Alter, Asier Sáez-Cirión, Jose Luis Diez-Martin, Elizabeth R Duke, Joshua T Schiffer, Annemarie Wensing, Javier Martinez-Picado","doi":"10.1016/S2352-3018(24)00090-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) markedly reduces HIV reservoirs, but the mechanisms by which this occurs are only partly understood. In this study, we aimed to describe the dynamics of virological and immunological markers of HIV persistence after allo-HSCT.</p><p><strong>Methods: </strong>In this prospective observational cohort study, we analysed the viral reservoir and serological dynamics in IciStem cohort participants with HIV who had undergone allo-HSCT and were receiving antiretroviral therapy, ten of whom had received cells from donors with the CCR5Δ32 mutation. Participants from Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK were included in the cohort both prospectively and retrospectively between June 1, 2014 and April 30, 2019. In the first 6 months after allo-HSCT, participants had monthly assessments, with annual assessments thereafter, with the protocol tailored to accommodate for the individual health status of each participant. HIV reservoirs were measured in blood and tissues and HIV-specific antibodies were measured in plasma. We used the Wilcoxon signed-rank test to compare data collected before and after allo-HSCT in participants for whom longitudinal data were available. When the paired test was not possible, we used the Mann-Whitney U test. We developed a mathematical model to study the factors influencing HIV reservoir reduction in people with HIV after allo-HSCT.</p><p><strong>Findings: </strong>We included 30 people with HIV with haematological malignancies who received a transplant between Sept 1, 2009 and April 30, 2019 and were enrolled within the IciStem cohort and included in this analysis. HIV reservoirs in peripheral blood were reduced immediately after full donor chimerism was achieved, generally accompanied by undetectable HIV-DNA in bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype. HIV-specific antibody levels and functionality values declined more slowly than direct HIV reservoir values, decaying significantly only months after full donor chimerism. Mathematical modelling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after massive reservoir reduction during conditioning chemotherapy before allo-HSCT (half-life of latently infected replication-competent cells decreased from 44 months to 1·5 months).</p><p><strong>Interpretation: </strong>Our work provides, for the first time, data on the effects of allo-HSCT in the context of HIV infection. Additionally, we raise the question of which marker can serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT.</p><p><strong>Funding: </strong>amfAR (American Foundation for AIDS Research; ARCHE Program), National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Dutch Aidsfonds.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"11 6","pages":"e389-e405"},"PeriodicalIF":12.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417461/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.\",\"authors\":\"Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera, Björn-Erik Ole Jensen, Linos Vandekerckhove, Manuel Jurado, Kavita Raj, Julian Schulze Zur Wiesch, Rebeca Bailén, Johanna M Eberhard, Mitja Nabergoj, Gero Hütter, Raquel Saldaña-Moreno, Sharon Oldford, Lisa Barrett, Maria Luisa Montes Ramirez, Salisu Garba, Ravi Kumar Gupta, Boris Revollo, Christelle Ferra-Coll, Jurgen Kuball, Galit Alter, Asier Sáez-Cirión, Jose Luis Diez-Martin, Elizabeth R Duke, Joshua T Schiffer, Annemarie Wensing, Javier Martinez-Picado\",\"doi\":\"10.1016/S2352-3018(24)00090-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) markedly reduces HIV reservoirs, but the mechanisms by which this occurs are only partly understood. In this study, we aimed to describe the dynamics of virological and immunological markers of HIV persistence after allo-HSCT.</p><p><strong>Methods: </strong>In this prospective observational cohort study, we analysed the viral reservoir and serological dynamics in IciStem cohort participants with HIV who had undergone allo-HSCT and were receiving antiretroviral therapy, ten of whom had received cells from donors with the CCR5Δ32 mutation. Participants from Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK were included in the cohort both prospectively and retrospectively between June 1, 2014 and April 30, 2019. In the first 6 months after allo-HSCT, participants had monthly assessments, with annual assessments thereafter, with the protocol tailored to accommodate for the individual health status of each participant. HIV reservoirs were measured in blood and tissues and HIV-specific antibodies were measured in plasma. We used the Wilcoxon signed-rank test to compare data collected before and after allo-HSCT in participants for whom longitudinal data were available. When the paired test was not possible, we used the Mann-Whitney U test. We developed a mathematical model to study the factors influencing HIV reservoir reduction in people with HIV after allo-HSCT.</p><p><strong>Findings: </strong>We included 30 people with HIV with haematological malignancies who received a transplant between Sept 1, 2009 and April 30, 2019 and were enrolled within the IciStem cohort and included in this analysis. HIV reservoirs in peripheral blood were reduced immediately after full donor chimerism was achieved, generally accompanied by undetectable HIV-DNA in bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype. HIV-specific antibody levels and functionality values declined more slowly than direct HIV reservoir values, decaying significantly only months after full donor chimerism. Mathematical modelling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after massive reservoir reduction during conditioning chemotherapy before allo-HSCT (half-life of latently infected replication-competent cells decreased from 44 months to 1·5 months).</p><p><strong>Interpretation: </strong>Our work provides, for the first time, data on the effects of allo-HSCT in the context of HIV infection. Additionally, we raise the question of which marker can serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT.</p><p><strong>Funding: </strong>amfAR (American Foundation for AIDS Research; ARCHE Program), National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Dutch Aidsfonds.</p>\",\"PeriodicalId\":48725,\"journal\":{\"name\":\"Lancet Hiv\",\"volume\":\"11 6\",\"pages\":\"e389-e405\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417461/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Hiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/S2352-3018(24)00090-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2352-3018(24)00090-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:同种异体造血干细胞移植(allo-HSCT)可显著减少艾滋病病毒库,但人们对其发生机制仅有部分了解。在这项研究中,我们旨在描述异体造血干细胞移植后艾滋病病毒存留的病毒学和免疫学标志物的动态变化:在这项前瞻性队列观察研究中,我们分析了 IciStem 队列中接受过异体 HSCT 并正在接受抗逆转录病毒治疗的 HIV 感染者的病毒库和血清学动态,其中 10 人接受了来自 CCR5Δ32 突变供体的细胞。2014年6月1日至2019年4月30日期间,来自比利时、加拿大、德国、意大利、荷兰、西班牙、瑞士和英国的参与者以前瞻性和回顾性的方式被纳入队列。在allo-HSCT后的前6个月,参与者每月进行一次评估,之后每年进行一次评估,评估方案根据每位参与者的个体健康状况进行调整。我们在血液和组织中测量了艾滋病毒储库,在血浆中测量了艾滋病毒特异性抗体。我们使用 Wilcoxon 符号秩检验来比较异体 HSCT 前后收集到的数据,这些参与者都有纵向数据。如果无法进行配对检验,我们则使用曼-惠特尼 U 检验。我们建立了一个数学模型,以研究影响异体 HSCT 后 HIV 感染者体内 HIV 储库减少的因素:我们纳入了 30 名在 2009 年 9 月 1 日至 2019 年 4 月 30 日期间接受移植的血液恶性肿瘤艾滋病病毒感染者,他们都在 IciStem 队列中登记并纳入了此次分析。无论供体的 CCR5 基因型如何,外周血中的 HIV 储库在供体完全嵌合后立即减少,同时骨髓、回肠、淋巴结和脑脊液中通常检测不到 HIV DNA。艾滋病毒特异性抗体水平和功能值的下降速度比直接艾滋病毒储库值的下降速度慢,在供体完全嵌合后数月才显著下降。数学模型表明,在同种异体造血干细胞移植前的条件化疗期间,病毒库大量减少(潜伏感染复制能力细胞的半衰期从 44 个月降至 1-5 个月),而供体细胞介导的异体免疫是病毒库耗竭的主要机制:我们的研究首次提供了有关艾滋病病毒感染情况下异体造血干细胞移植效果的数据。此外,我们还提出了哪种标记物可以作为残余病毒血症的最后报告者的问题,并推测异体HSCT后T细胞免疫反应的缺失可能是比抗体下降更可靠的标记物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.

Background: Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) markedly reduces HIV reservoirs, but the mechanisms by which this occurs are only partly understood. In this study, we aimed to describe the dynamics of virological and immunological markers of HIV persistence after allo-HSCT.

Methods: In this prospective observational cohort study, we analysed the viral reservoir and serological dynamics in IciStem cohort participants with HIV who had undergone allo-HSCT and were receiving antiretroviral therapy, ten of whom had received cells from donors with the CCR5Δ32 mutation. Participants from Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK were included in the cohort both prospectively and retrospectively between June 1, 2014 and April 30, 2019. In the first 6 months after allo-HSCT, participants had monthly assessments, with annual assessments thereafter, with the protocol tailored to accommodate for the individual health status of each participant. HIV reservoirs were measured in blood and tissues and HIV-specific antibodies were measured in plasma. We used the Wilcoxon signed-rank test to compare data collected before and after allo-HSCT in participants for whom longitudinal data were available. When the paired test was not possible, we used the Mann-Whitney U test. We developed a mathematical model to study the factors influencing HIV reservoir reduction in people with HIV after allo-HSCT.

Findings: We included 30 people with HIV with haematological malignancies who received a transplant between Sept 1, 2009 and April 30, 2019 and were enrolled within the IciStem cohort and included in this analysis. HIV reservoirs in peripheral blood were reduced immediately after full donor chimerism was achieved, generally accompanied by undetectable HIV-DNA in bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype. HIV-specific antibody levels and functionality values declined more slowly than direct HIV reservoir values, decaying significantly only months after full donor chimerism. Mathematical modelling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after massive reservoir reduction during conditioning chemotherapy before allo-HSCT (half-life of latently infected replication-competent cells decreased from 44 months to 1·5 months).

Interpretation: Our work provides, for the first time, data on the effects of allo-HSCT in the context of HIV infection. Additionally, we raise the question of which marker can serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT.

Funding: amfAR (American Foundation for AIDS Research; ARCHE Program), National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Dutch Aidsfonds.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lancet Hiv
Lancet Hiv IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES
CiteScore
19.90
自引率
4.30%
发文量
368
期刊介绍: The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信